Health Canada Post-Market Surveillance Requirements: CMDR, MDSAP, and Medical Device Compliance

What Is Health Canada Post-Market Surveillance?

Health Canada's post-market surveillance system for medical devices is the systematic process of monitoring device safety and performance after market authorization in Canada. Overseen by the Therapeutic Products Directorate (TPD) and the Medical Devices Bureau, Canada's PMS framework is built on the Food and Drugs Act and the Canadian Medical Devices Regulations (CMDR, SOR/98-282).

Unlike the U.S., where FDA conducts its own inspections, Canada relies on the Medical Device Single Audit Program (MDSAP) for quality system oversight. MDSAP audits include a dedicated post-market surveillance chapter (Chapter 5) that evaluates how manufacturers collect, analyze, and act on post-market data.

The Regulatory Framework

Food and Drugs Act (F&DA)

The Food and Drugs Act is the overarching legislation governing medical devices in Canada. Sections 19-21 deal with recalls and the prohibition of unsafe devices. Section 21.3 grants Health Canada the authority to order a recall when a device poses a serious or imminent risk to health.

CMDR (SOR/98-282) — Canadian Medical Devices Regulations

The CMDR is the core regulation governing medical devices. Sections 59-64 establish mandatory problem reporting requirements. A "mandatory problem" includes any incident where a device has caused or could cause death, serious deterioration in health, or where the device has a deficiency that could lead to either outcome.

Medical Device Single Audit Program (MDSAP)

Since January 2019, Health Canada requires MDSAP certification for all Class II, III, and IV medical device manufacturers. MDSAP audits cover five regulatory authorities (Australia, Brazil, Canada, Japan, United States) and include Chapter 5 specifically dedicated to post-market surveillance. This chapter evaluates the manufacturer's PMS plan, complaint handling, trend analysis, and regulatory reporting processes.

Who Must Comply

• Medical Device Establishment Licence (MDEL) holders: Must report mandatory problems, maintain PMS systems, and ensure devices on the market continue to meet safety requirements.
• Importers (MDEL holders): Must report problems encountered in Canada to Health Canada and forward information to manufacturers.
• Manufacturers (foreign and domestic): Must obtain MDSAP certification (Class II-IV), maintain a PMS system, and report mandatory problems.
• Healthcare facilities: Encouraged (but not mandated) to report incidents through the Canada Vigilance Program.

Key Requirements

Reporting Timelines

1. Preliminary report: Within 10 calendar days of becoming aware of a mandatory problem.
2. Final report: Within a period specified by Health Canada (typically 30 days, but varies based on the nature of the event).
3. Immediate notification: As soon as possible for incidents posing serious and imminent risk to health (CMDR section 64).
4. Annual licence renewal: MDEL holders must renew before the expiry of their current Medical Device Establishment Licence.

MDSAP Audit Focus Areas for PMS (Chapter 5)

During MDSAP audits, Chapter 5 specifically evaluates post-market surveillance practices. Auditors assess:

• A documented PMS plan that defines data sources, collection frequency, and analysis methods
• Evidence of monitoring regulatory signals from Health Canada — including recalls, safety advisories, and licence changes
• A complaint handling system with documented investigation and reportability assessment for each complaint
• Trend analysis of complaints, adverse events, and field corrections — not just individual case reviews
• Feedback loop to the risk management file (ISO 14971) demonstrating that PMS findings update risk assessments
• CAPA effectiveness verification linked to PMS data, showing that corrective actions actually resolved the identified issues

Common Compliance Gaps

1. Not monitoring Health Canada recalls and advisories for similar or predicate devices — Manufacturers often monitor only their own complaints, missing critical signals from the broader market.
2. Complaint files without documented determination of mandatory problem reportability — Every complaint must include a documented assessment of whether it constitutes a mandatory problem under CMDR sections 59-61.
3. No evidence of trend analysis — MDSAP Chapter 5 explicitly requires trend analysis. Individual complaint review is not sufficient.
4. MDALL licence lapsed or not updated after significant device changes — Licence maintenance is an ongoing obligation, not a one-time task.
5. PMS plan exists but doesn't define specific external data sources to monitor — A generic PMS procedure that says "monitor external data" without specifying which sources and how often is insufficient for MDSAP auditors.
6. CAPA system disconnected from PMS findings — PMS data must feed into the CAPA process. Many manufacturers treat complaint handling and CAPA as separate workflows.

How TrueMedDevice Helps

TrueMedDevice monitors 3 Health Canada data sources — recalls (10,301 records), MDALL licences (72,640 records), and MDL device listings (142,250 records) — providing comprehensive coverage of the Canadian regulatory landscape. Combined with 4 FDA sources (323,000+ records), the platform offers dual-market monitoring from a single dashboard.

• Take the free PMS Gap Assessment — Evaluate your compliance against 30 PMS requirements covering both FDA and Health Canada.
• Try a free demo — See real Health Canada and FDA signals matched to your device. No account required.
• View pricing — Monitoring subscriptions start at $199/month for US-only or $259/month for US + Canada coverage.

Related Resources

• FDA Post-Market Surveillance Requirements
• FDA vs Health Canada PMS Requirements — Side-by-Side Comparison
• PMS Monitoring Tool
• FDA Recall Monitoring